Half of requests for complex dental work are being rejected under national insurance plan
Health Canada says 52 per cent of requests for pre-authorized dental work between November 2024 and June 2025 have been rejected.
While the vast majority of claims don't need pre-authorization, it's required for more complex and often more expensive procedures, like crowns or partial dentures. Clinics must submit extra documentation like X-rays and dental charts to show the work is medically necessary before it can be covered and completed.
"There's been a lot of confusion for dentists who send in what we would normally send in to a private plan, and it comes back rejected," said Dr. Bruce Ward, a Vancouver dentist and president of the Canadian Dental Association.
"It's a much, much, much higher rejection rate than private plans."
The multibillion-dollar Canadian Dental Care Plan helps cover the cost of dental work for Canadian residents with a family income below $90,000 who don't have access to private insurance. The program fully expanded to cover people aged 18 to 64 last month.
Health Canada says 5.2 million people have been approved for coverage so far, but only about half — 2.2 million — have received care.
And some new patients are getting an unexpected bill, while certain parts of the country are struggling to keep up with a huge influx of appointments, Ward said.
Still, providers told CBC News the program is providing Canadians much-needed access to care — and that issues with the program are improving.
Clinics submit the pre-authorizations through Sun Life, the insurance provider that the federal government contracted to run the program.
Dental offices are sometimes waiting weeks or months for a response, only to be told Sun Life needs additional documentation — further slowing down the process, Ward said.
"A lot of people have been waiting for crowns to be pre-authorized," Ward said. "There was an avalanche of approvals that got sent in."
Health Canada said rejections and delays in pre-authorizations are caused by several factors, including an unexpected high volume of submissions that were missing information.
Oral health-care providers also tell CBC News there were many technical issues with the submission software that have since been largely resolved.
Health Canada has worked to streamline the process and educate providers about how to complete the applications, a spokesperson said.
Eighty per cent of the pre-authorizations are now being processed within seven business days. And more than 90 per cent of the claims, like basic cleanings or fillings, don't require pre-authorization.
But Donna Wells, manager of professional practice at the Canadian Dental Hygienists Association, said the program needs to better cover preventive care.
The plan currently allots one hour of scaling per year for adults. Teenagers get just 15 minutes of scaling.
"These are patients who have not had oral health care, in some cases, for a number of years, because it's been such a financial barrier for them," Wells said.
She said pre-authorization applications for additional scaling are being rejected en masse.
Health Canada says over a million Canadians signed on to the program when it expanded in June, and 94,980 of them received dental care.
But that influx of patients has led to a backlog in some parts of the country, like Atlantic Canada."This program is wonderful, but it's putting a strain on providers," said Natalie Marsh, a dental assistant in North Sydney, N.S., and vice-president of the Canadian Dental Assistants Association.
She said her clinic is already booking appointments for spring 2026.
"You're seeing people who haven't seen a dentist in a long time. So they're coming in with a lot of work to be done," she said.
Providers said patients continue to be under the impression their dental work will be free of charge. But the program reimburses clinics at a rate lower than provincial fee guides, which they often use to set their rates.
That means dental offices can "balance bill," charging the difference between the price of the procedure and what Ottawa will pay them.
"I just had somebody in my office a couple of weeks ago who was very upset, because they'd been told that they were covered 100 per cent," Ward said.
Ward said patients, including seniors, should remember they need to reapply every year.
Despite those challenges, Ward said overall he's found the dental care plan to be "very good" to work with. That sentiment is echoed by other oral health associations.
"It's been a huge boon to a lot of people who frankly would never have been able to afford to have their mouths taken care of," Ward said.
"It's remarkable," he said. "And yes, there's going to be some growing pains."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Market Surges Amid Rising Liver Disease and Cancer Prevalence
The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Ocelot Bio and Regeneron Pharmaceuticals, are innovating to improve treatment efficacy. With increasing demand in emerging markets and an aging population, the ascites market is set for sustained growth. Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ascites market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers for the ascites market is the rising prevalence of liver diseases, particularly cirrhosis, as well as various forms of cancer, such as liver, ovarian, and pancreatic cancer. As these diseases are among the leading causes of ascites, their increasing incidence globally is driving the demand for diagnostic tools and treatment options. The global rise in lifestyle diseases, alcohol consumption, and hepatitis infections has contributed to this increase, which in turn propels the growth of the ascites market. As the ascites market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The aging global population is another significant factor driving the ascites market. Older adults are more prone to liver diseases, heart failure, and cancer, all of which are major risk factors for ascites. As the number of elderly individuals increases, the prevalence of ascites is expected to rise, further driving the demand for effective treatments and management strategies. Leading players in the global ascites market, such as Ocelot Bio, Regeneron Pharmaceuticals, and BioVie Inc., are continuously focusing on several strategies to maintain their competitive edge and drive growth. These strategies include continuous technological innovation, such as the development of more advanced and efficient treatment options, mapping systems, and imaging technologies. These companies aim to enhance the safety and efficacy of ascites treatment competitive landscape of the global ascites market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the ascites market will continue to evolve, fostering new opportunities for both established and emerging the development and improvement of diagnostic technologies, including imaging techniques like ultrasound, CT scans, and the use of paracentesis for fluid analysis, are major drivers for the ascites market. Early detection and accurate diagnosis allow for timely intervention, improving treatment outcomes. The availability of non-invasive and highly sensitive diagnostic tests increases the likelihood of diagnosing ascites in its early stages, expanding the demand for related treatment and management the positive growth trajectory, several challenges continue to impact the global ascites market. One of the primary challenges is the high cost of treatments, particularly for advanced interventions such as liver transplants, chemotherapy, and some novel drug therapies. These costs can be a significant barrier to access, especially in developing regions where healthcare infrastructure may be limited, and insurance coverage for expensive treatments may not be available. This high cost can restrict the market growth, as many patients may not be able to afford the necessary side effects and complications of treatment further restrict the market growth. Several treatments for ascites, including diuretics and paracentesis, can lead to complications or side effects, such as electrolyte imbalances, infections, or low blood pressure. These potential risks may deter patients from seeking treatment or adhering to prescribed regimens, thus limiting the overall demand for these interventions. Additionally, the invasive nature of some treatments, such as the need for repeated paracentesis, can be uncomfortable for patients and may result in decreased willingness to pursue these conclusion, the global ascites market is expected to see steady growth, driven by the increasing prevalence of underlying conditions such as liver diseases and cancers, as well as advancements in diagnostic and therapeutic options. Continued research and innovation in targeted treatments, along with a growing focus on early detection, will be key to improving patient outcomes and reducing the burden of ascites on healthcare systems. As stakeholders, including pharmaceutical companies, healthcare providers, and researchers, continue to work toward better management strategies, the market will evolve to offer more effective solutions, ultimately enhancing the quality of life for patients and addressing the ongoing challenges posed by this Topics Covered: 1. Global Ascites Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology of Ascites1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Ascites Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Ascites Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Ascites Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Ascites Market, by Country2.3.3.1.1 Japan3. Global Ascites Market: Competitive Landscape and Company Profiles3.1 Key Development and Strategies3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Ocelot Bio3.2.1.1 Overview3.2.1.2 Top Products / Product Portfolio3.2.1.3 Target Customers/End-Users3.2.1.4 Key Personnel3.2.1.5 Analyst View3.2.2 PharmaIN3.2.3 Grifols Therapeutics LLC.3.2.4 Regeneron Pharmaceuticals.3.2.5 BioVie Inc4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Trump's spending bill will likely boost costs for insurers, shrink Medicaid coverage
By Amina Niasse NEW YORK (Reuters) -President Donald Trump's spending bill is set to raise administrative costs and make managing costs more difficult for insurers like UnitedHealthcare and CVS Health's Aetna that operate Medicaid health plans, experts say. As a result, those insurers will likely pull back their Medicaid coverage and invest more in existing markets to retain their healthier members, experts said. States contract with insurers, including UnitedHealth Group's UnitedHealthcare, CVS Health's Aetna, Centene and Molina , to operate Medicaid plans that are jointly funded by state and federal governments. Almost all of Molina's and nearly half of Centene's insurance business is composed of Medicaid members. That portion is smaller for Aetna and UnitedHealthcare which operate large commercial businesses. Seven industry experts say the bill's funding cuts and its stipulation requiring states to verify patients' work status deliver a blow to insurers. The provision in Trump's One Big Beautiful Bill Act requires low-income adults, in states that have expanded Medicaid coverage under the Affordable Care Act, to prove every six months that they meet work requirements in order to maintain coverage. State Medicaid departments, grappling with scant operational teams, will have a difficult time carrying out verification protocols, five industry experts said. "The expectation is that states are going to have to be ready by 2026 or 2027, and that's a fast turnaround window," said Nikita Singareddy, CEO of healthcare platform Fortuna Health. A spokesperson for Centene said it would work with federal and state partners to help patients navigate change. A spokesperson for CVS Health declined to comment. UnitedHealth Group and Molina did not immediately respond to a Reuters request for comment. For insurers, the disruptions could result in more sick people enrolled in the Medicaid plans they operate on behalf of the government because those who are more ill are likely to complete the verification process because they have an immediate need for healthcare, industry experts and an investor said. The Congressional Budget Office estimated Medicaid policy changes in the bill could leave 7.8 million people uninsured by 2034. Mass disenrollments could begin in 2027 on a rolling basis, according to an expert at a state policy organization. The White House did not immediately respond to a request for comment. States may choose to pay companies operating health plans at lower rates due to funding cuts, said Eric Levine, a principal consultant at Avalere Health. Following the COVID-19 pandemic, insurers have said the rates they are paid by states have not caught up to actual cost of care. Disenrollments of healthy people may exacerbate this misalignment, leading to inaccurate rates paid to plans and squeezed profit margins, according to a spokesperson for a national insurance trade organization and an investor. 'ANOTHER PERIOD OF RETRENCHMENT' If insurers find the fallout from these changes daunting, they are likely to exit certain markets or pull back on bidding or competing for footprints in new areas. "Insurers will continue to be more cautious about not just entering any new states, but retrenching just in the states where they have the highest market share, most scale and more profitable business," said Jeff Jonas, a portfolio manager at Gabelli Funds, which owns shares of UnitedHealth Group. In an effort to keep healthier patients that drive profits enrolled, insurers may employ plan design changes ahead of the bill's finalization, adding perks that can make enrollment more appealing. This could help insurers retain and attract healthy members, according to Matt Salo, CEO of Salo Health Strategies and founding director of the National Association of Medicaid Directors and two other policy experts. Hosting volunteer events and job or educational search services are strategies insurers may use to engage members and reduce losses, said Levine. Health plans are also expected to boost transportation benefits and other social-need benefits for low-income Americans. Jonas and a spokesperson for a national health insurer say this programming will boost administrative costs in the short-term. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Washington Post
an hour ago
- Washington Post
As a gastroenterologist, here's what I eat in a day to boost my gut health
You talk a lot about how important it is to eat a high-fiber diet but that most Americans don't meet their daily recommended fiber goals. I'm curious what you personally do to reach that goal. Many of my patients automatically picture a 'high-fiber diet' as a life of kale salads and never seeing a slice of white toast again.